Hinge Health (HNGE) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
17 Apr, 2026Executive summary
The annual meeting will be held virtually on June 3, 2026, with voting on director elections and auditor ratification.
Record date for voting is April 10, 2026; proxy materials are available online.
Holders of Class A, Class B, and Series E preferred stock may vote, with different voting rights per class.
Voting matters and shareholder proposals
Stockholders will vote on electing two Class I directors (Teddie Wardi and Tyler Sloat) for terms expiring in 2029.
Ratification of Deloitte & Touche LLP as independent auditor for 2026 is on the agenda.
Board recommends voting for all director nominees and for auditor ratification.
Board of directors and corporate governance
Board consists of six members, with a majority being independent; all committees are fully independent.
Board is classified into three staggered classes, each serving three-year terms.
Committees include Audit, Compensation, and Nominating and Corporate Governance, each with defined charters.
Annual self-evaluations and regular executive sessions are conducted.
Board diversity is considered, though no formal diversity policy exists.
Latest events from Hinge Health
- Record 2025 revenue, 83% gross margin, and 97% retention; strong 2026 outlook.HNGE
Q4 202521 Apr 2026 - Vote virtually by June 3, 2026, on director elections and auditor ratification.HNGE
Proxy filing17 Apr 2026 - IPO highlights strong growth, high retention, and tech-driven MSK care with dual-class structure.HNGE
Registration Filing29 Nov 2025 - AI-driven MSK care platform posts 33% revenue growth, strong margins, and targets global expansion.HNGE
Registration Filing29 Nov 2025 - IPO targets $230M+ net proceeds, strong growth, but most funds go to RSU tax obligations.HNGE
Registration Filing29 Nov 2025 - Digital MSK care platform targets $230.7M IPO, focusing on growth and tax obligations.HNGE
Registration Filing29 Nov 2025 - AI-driven MSK care platform with rapid growth and high retention targets $18B+ market in IPO.HNGE
Registration Filing29 Nov 2025 - Q2 2025 revenue rose 55% to $139.1M, with strong margins and IPO-related net loss.HNGE
Q2 202523 Nov 2025 - Q3 revenue up 53% to $154.2M, margins and cash flow surged, guidance raised for 2025.HNGE
Q3 202513 Nov 2025